Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials

References

• Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev. 2011;(9):CD003429.
   PubMed Web of Science ®Google Scholar
• Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295–308. doi:10.1177/2040620718796429
   PubMed Web of Science ®Google Scholar
• Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol. 2018;11(8):673–683. doi:10.1080/17474086.2018.1489719
   PubMed Web of Science ®Google Scholar
• Jiménez-Yuste V, Auerswald G, Benson G, et al. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfusion. 2014;12(3):314–319.
   PubMed Web of Science ®Google Scholar
• Walsh C, Coppens M, Escobar M, Wang M. Optimal trough levels in haemophilia B: raising expectations. Haemophilia. 2020;26(6):e334–e336. doi:10.1111/hae.14098
   Web of Science ®Google Scholar
• Shapiro A, Potts J, Li SV, et al. Association of bleeding tendency with time under target FIX activity levels in severe hemophilia B Patients treated with recombinant factor IX Fc fusion protein [abstract]. Blood. 2013;122(21):2349. doi:10.1182/blood.V122.21.2349.2349
   Web of Science ®Google Scholar
• Tjärnlund-Wolf A, Lassila R. Phenotypic characterization of haemophilia B - Understanding the underlying biology of coagulation factor IX. Haemophilia. 2019;25(4):567–574.
   PubMed Web of Science ®Google Scholar
• Iorio A, Fischer K, Blanchette V, et al. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost. 2017;117(6):1023–1030. doi:10.1160/TH16-12-0942
   PubMed Web of Science ®Google Scholar
• Sanofi Genzyme. Alprolix Prescribing Information; Published 2017. Available from: http://products.sanofi.us/Alprolix/alprolix.html. Accessed November 2020.
   Google Scholar
• European Medicines Agency. Alprolix Summary of Product Characteristics; Published 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf. Accessed November 2020.
   Google Scholar
• Fischer K, Kulkarni R, Nolan B, et al. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017;4(2):e75–e82. doi:10.1016/S2352-3026(16)30193-4
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313–2323. doi:10.1056/NEJMoa1305074
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Fischer K, Ragni M, et al. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B-YOND extension study. Haemophilia. 2020;26(6):e262–e271. doi:10.1111/hae.14036
   Web of Science ®Google Scholar
• Shapiro AD, Pasi KJ, Ozelo MC, et al. Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B. Res Pract Thromb Haemost. 2019;3(1):109–113. doi:10.1002/rth2.12163
   Web of Science ®Google Scholar
• CSL Behring. Idelvion Prescribing Information; Published 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf. Accessed November 2020.
   Google Scholar
• European Medicines Agency. Idelvion Summary of Product Characteristics; Published 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf. Accessed November 2020.
   Google Scholar
• Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761–1769. doi:10.1182/blood-2015-09-669234
   PubMed Web of Science ®Google Scholar
• Kenet G, Chambost H, Male C, et al. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. Thromb Haemost. 2016;116(4):659–668. doi:10.1160/TH16-03-0179
   PubMed Web of Science ®Google Scholar
• Kenet G, Chambost H, Male C, et al. Long-term safety and efficacy of recombinant coagulation factor ix albumin fusion protein (rIX-FP) in previously treated pediatric patients with hemophilia B: results from a Phase 3b extension study. Thromb Haemost. 2020;120(4):599–606. doi:10.1055/s-0040-1705116
   PubMed Web of Science ®Google Scholar
• Mancuso ME, Lubetsky A, Pan-Petesch B, et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost. 2020;18(5):1065–1074. doi:10.1111/jth.14778
   PubMed Web of Science ®Google Scholar
• Chaimani A, Caldwell DM, Higgins JPT, et al. Chapter 11: undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.1 Ed. Cochrane; 2020.
   Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947. doi:10.1016/j.jval.2012.05.004
   PubMed Web of Science ®Google Scholar
• NICE Decision Support Unit. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE; Published 2016. Available from: http://nicedsu.org.uk/technical-support-documents/population-adjusted-indirect-comparisons-maic-and-stc/. Accessed November 2020.
   Google Scholar
• Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl. 1965;Suppl 77:73–132.
   Google Scholar
• Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia. 2004;10(6):689–697. doi:10.1111/j.1365-2516.2004.01036.x
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar